ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Effectiveness of T therapy in hypogonadal patients and its controversial adverse impact on the cardiovascular system
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 182575" data-attributes="member: 13851"><p><strong><span style="color: rgb(184, 49, 47)">Effectiveness of testosterone therapy in hypogonadal patients and its controversial adverse impact on the cardiovascular system </span></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong>ABSTRACT </strong></p><p></p><p>Testosterone is the major male hormone produced by testicles that are directly associated with man’s appearance and secondary sexual developments. Androgen deficiency starts when the male hormonal level falls from its normal range though, in youngsters, the deficiency occurs due to disruption of the normal functioning of pituitary, hypothalamus glands, and testes. Thus, testosterone replacement therapy was already known for the treatment of androgen deficiency with lesser risks of producing cardiovascular problems. Since from previous years, the treatment threshold in the form of testosterone replacement therapy has effectively increased to that extent that it was prescribed for those conditions which it was considered inappropriate. However, there are some research studies and clinical trials available that proposed a higher risk of inducing cardiovascular disease with the use of testosterone replacement therapy. Thus under the light of these results, the FDA has published the report of the increased risk of cardiovascular disease with the increased use of testosterone replacement therapy. Nevertheless, there is not a single trial available or designed that could evaluate the risk of cardiovascular events with the use of testosterone replacement therapy. As a result, the use of testosterone still questioned the cardiovascular safety of this replacement therapy. Thus, this literature outlines the distribution pattern of disease by investigating the data and link between serum testosterone level and the cardiovascular disease, also the prescription data of testosterone replacement therapy patients and their tendency of inducing cardiovascular disease, meta-analysis and the trials regarding testosterone replacement therapy and its connection with the risks of causing cardiovascular disease and lastly, the possible effects of testosterone replacement therapy on the cardiovascular system. This study aims to evaluate the available evidence regarding the use of testosterone replacement therapy when choosing it as a treatment plan for their patients</p><p></p><p></p><p></p><p></p><p><strong>Effect of endogenous testosterone on the cardiovascular events – <span style="color: rgb(184, 49, 47)">The TRNASVERSE trial </span></strong></p><p></p><p><span style="color: rgb(184, 49, 47)"><strong><em>TRAVERSE trial (US National Library of Medicine) </em></strong><em>is known as the first randomized controlled trial that is used to analyze the cardiovascular events that occurred due to testosterone replacement therapy. </em></span><em><span style="color: rgb(44, 130, 201)">Thus, to start these trials in 2018 researchers plan a scheme with 6000 men ranging between 45 and 80 years of age who were at risk of cardiovascular disease were treated with testosterone <300 ng/dl in gel form or treated with placebo. <strong>The treatment period selected for this plan was 5 years and the foremost endpoint selected for this study was MACE (nonfatal MI, nonfatal stroke, or death from cardiovascular causes).</strong> <strong>The other secondary results are achieved from the occurrence of the cardiovascular endpoint. <u>The findings associated with these trials provide the documented results of cardiovascular safety by the use of testosterone replacement therapy</u>. </strong></span></em></p><p></p><p></p><p></p><p></p><p><strong>Conclusions </strong></p><p></p><p><em><span style="color: rgb(184, 49, 47)">T plays an important role in regulating body functions which include the cardiovascular system and metabolic system of the body.</span></em> <em><span style="color: rgb(44, 130, 201)">However, the population study contradicts the collected data and the clinical trials conducted yet. There are many studies still present that corroborate the facts about mortality due to testosterone replacement therapy. While several other studies in randomized trials documented the increased severity of cardiovascular risks due to testosterone therapy. Some contradictions were also seen in meta-analyses and were constrained in the range of low to medium trials.</span></em> <span style="color: rgb(44, 130, 201)"><strong><em>In addition, till now there is no authentic publication or research available that has the capability to evaluate its effect on cardiovascular risks associated with T. Thus for this purpose, a TRAVERSE trial (US National Library of Medicine) uses long-term treatment and the conclusions for the evaluation of cardiovascular events produced due to testosterone therapy.</em></strong></span> <em><strong><span style="color: rgb(44, 130, 201)">Thus, it is necessary to make patients aware of the cardiovascular events induced by testosterone replacement therapy. </span></strong></em></p></blockquote><p></p>
[QUOTE="madman, post: 182575, member: 13851"] [B][COLOR=rgb(184, 49, 47)]Effectiveness of testosterone therapy in hypogonadal patients and its controversial adverse impact on the cardiovascular system [/COLOR] ABSTRACT [/B] Testosterone is the major male hormone produced by testicles that are directly associated with man’s appearance and secondary sexual developments. Androgen deficiency starts when the male hormonal level falls from its normal range though, in youngsters, the deficiency occurs due to disruption of the normal functioning of pituitary, hypothalamus glands, and testes. Thus, testosterone replacement therapy was already known for the treatment of androgen deficiency with lesser risks of producing cardiovascular problems. Since from previous years, the treatment threshold in the form of testosterone replacement therapy has effectively increased to that extent that it was prescribed for those conditions which it was considered inappropriate. However, there are some research studies and clinical trials available that proposed a higher risk of inducing cardiovascular disease with the use of testosterone replacement therapy. Thus under the light of these results, the FDA has published the report of the increased risk of cardiovascular disease with the increased use of testosterone replacement therapy. Nevertheless, there is not a single trial available or designed that could evaluate the risk of cardiovascular events with the use of testosterone replacement therapy. As a result, the use of testosterone still questioned the cardiovascular safety of this replacement therapy. Thus, this literature outlines the distribution pattern of disease by investigating the data and link between serum testosterone level and the cardiovascular disease, also the prescription data of testosterone replacement therapy patients and their tendency of inducing cardiovascular disease, meta-analysis and the trials regarding testosterone replacement therapy and its connection with the risks of causing cardiovascular disease and lastly, the possible effects of testosterone replacement therapy on the cardiovascular system. This study aims to evaluate the available evidence regarding the use of testosterone replacement therapy when choosing it as a treatment plan for their patients [B]Effect of endogenous testosterone on the cardiovascular events – [COLOR=rgb(184, 49, 47)]The TRNASVERSE trial [/COLOR][/B] [COLOR=rgb(184, 49, 47)][B][I]TRAVERSE trial (US National Library of Medicine) [/I][/B][I]is known as the first randomized controlled trial that is used to analyze the cardiovascular events that occurred due to testosterone replacement therapy. [/I][/COLOR][I][COLOR=rgb(44, 130, 201)]Thus, to start these trials in 2018 researchers plan a scheme with 6000 men ranging between 45 and 80 years of age who were at risk of cardiovascular disease were treated with testosterone <300 ng/dl in gel form or treated with placebo. [B]The treatment period selected for this plan was 5 years and the foremost endpoint selected for this study was MACE (nonfatal MI, nonfatal stroke, or death from cardiovascular causes).[/B] [B]The other secondary results are achieved from the occurrence of the cardiovascular endpoint. [U]The findings associated with these trials provide the documented results of cardiovascular safety by the use of testosterone replacement therapy[/U]. [/B][/COLOR][/I] [B]Conclusions [/B] [I][COLOR=rgb(184, 49, 47)]T plays an important role in regulating body functions which include the cardiovascular system and metabolic system of the body.[/COLOR][/I] [I][COLOR=rgb(44, 130, 201)]However, the population study contradicts the collected data and the clinical trials conducted yet. There are many studies still present that corroborate the facts about mortality due to testosterone replacement therapy. While several other studies in randomized trials documented the increased severity of cardiovascular risks due to testosterone therapy. Some contradictions were also seen in meta-analyses and were constrained in the range of low to medium trials.[/COLOR][/I] [COLOR=rgb(44, 130, 201)][B][I]In addition, till now there is no authentic publication or research available that has the capability to evaluate its effect on cardiovascular risks associated with T. Thus for this purpose, a TRAVERSE trial (US National Library of Medicine) uses long-term treatment and the conclusions for the evaluation of cardiovascular events produced due to testosterone therapy.[/I][/B][/COLOR] [I][B][COLOR=rgb(44, 130, 201)]Thus, it is necessary to make patients aware of the cardiovascular events induced by testosterone replacement therapy. [/COLOR][/B][/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Effectiveness of T therapy in hypogonadal patients and its controversial adverse impact on the cardiovascular system
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top